My hope is that he will go in the rare disease direction and cut costs/staff sooner rather then later. I think the problems had to go beyond Berkle and I didn't like that Margolin left (unless it was for reasons unrelated to the company).
I think they are fairly committed to the 1c in Q3 for 238 but I would love to get that off our plate even if it means we don't reap benefits till much later (approval/commercialization). Even though it was TKT's undoing I believe the Shire deal had us (TKT shareholders) getting 350-400 million for our share of the Epo product (if the buyout had fallen through) and basically that was for EU with the US patent situation. That was an approved product though at the time. I really don't have much other reference for a present value on this that is why I would take little cash up front for a very nice royalty and perhaps some nice regulatory milestones and someone picking up all costs and guarantee to move it forward.
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM